FAIR VALUE DISCLOSURES (Details Textual) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended
		Dec. 31, 2017	Feb. 28, 2017	Mar. 31, 2018	Mar. 31, 2017
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate				15.00%
Payments to Acquire Intangible Assets				$ 0	$ 50,956
Long-term Debt, Total				130,200
Finite-Lived Intangible Assets, Gross		$ 284,716		284,716
Inventory, Finished Goods, Gross	[1]	$ 13,901		8,914
Inderal XL [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			10.00%
Finite-Lived Intangible Assets, Gross			$ 15,100
Finite-Lived Intangible Asset, Useful Life			10 years
Acquisition Costs Capitalized			$ 40
Inventory, Finished Goods, Gross			5,000
Asset Acquisition Purchase Price			$ 20,200
InnoPran XL [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate			10.00%
Finite-Lived Intangible Assets, Gross			$ 19,000
Finite-Lived Intangible Asset, Useful Life			10 years
Acquisition Costs Capitalized			$ 100
Inventory, Finished Goods, Gross			11,600
Asset Acquisition Purchase Price			30,600
InnoPran XL [Member] | Cash [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets			600
InnoPran XL [Member] | Line of Credit [Member]
Fair Value Inputs, Assets, Quantitative Information
Payments to Acquire Intangible Assets			$ 30,000
Fair Value, Inputs, Level 1 [Member]
Fair Value Inputs, Assets, Quantitative Information
Notes Payable, Fair Value Disclosure				$ 156,600
AstraZeneca AB and AstraZeneca UK Limited [Member] | New Drug Applications [Member]
Fair Value Inputs, Assets, Quantitative Information
Fair Value Inputs, Discount Rate		10.00%
Payments to Acquire Intangible Assets		$ 46,500
Finite-Lived Intangible Assets, Gross		$ 46,700
Finite-Lived Intangible Asset, Useful Life		10 years
Acquisition Costs Capitalized		$ 200

[1] Includes finished goods acquired in asset purchases (Note 11).